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a  b  s  t  r  a  c  t
Cyanide  poisoning  by  accidental  or intentional  exposure  poses  a severe  health  risk.  The  current  Food  and
Drug  Administration  approved  antidotes  for cyanide  poisoning  can  be  effective,  but  each suffers  from
specific  major  limitations  concerning  large  effective  dosage,  delayed  onset  of  action,  or dependence  on
enzymes  generally  confined  to specific  organs.  Dimethyl  trisulfide  (DMTS),  a  sulfur donor  that  detoxifies
cyanide  by  converting  it into  thiocyanate  (a  relatively  nontoxic  cyanide  metabolite),  is a  promising  next
generation  cyanide  antidote.  Although  a validated  analytical  method  to  analyze  DMTS  from  any  matrix  is
not  currently  available,  one  will  be  vital  for the  approval  of DMTS  as  a therapeutic  agent  against  cyanide
poisoning.  Hence,  a stir  bar sorptive  extraction  (SBSE)  gas  chromatography  – mass  spectrometry  (GC–MS)
method  was  developed  and  validated  for the  analysis  of DMTS  from  rabbit  whole  blood.  Following  acid
denaturation  of  blood,  DMTS  was  extracted  into  a polydimethylsiloxane-coated  stir  bar.  The  DMTS  was
then thermally  desorbed  from  the  stir  bar and  analyzed  by GC–MS.  The limit of  detection  of  DMTS  using
this  method  was  0.06  M  with  dynamic  range  from  0.5–100  M.  For  quality  control  standards,  the  pre-
cision,  as  measured  by  percent  relative  standard  deviation,  was  below  10%,  and  the  accuracy  was within
15% of  the nominal  concentration.  The  method  described  here  will  allow  further  investigations  of  DMTS
as a promising  antidote  for cyanide  poisoning.
© 2016  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Cyanide (LD50, human = 1.5 mg/kg for an oral exposure;
LC50, human = 524 ppm for a 10 min  inhalation exposure to HCN) is
a rapidly acting, highly toxic compound that inhibits cytochrome
c oxidase and subsequently causes cellular hypoxia, which may
eventually result in death [1–6]. It can be introduced into the body
by a number of different ways, such as consumption of cyanogenic
plants and fruits [7–9] (e.g., cassava roots, yam, sorghum, bitter
almonds), inhalation of hydrogen cyanide gas from fire [10] (i.e.,
burning of acrylonitrile, polyurethane, wool, silk, rubber produces
HCN) and cigarette smoke, occupational exposures (e.g., the
2015 warehouse explosion in Tianjin, China [11,12]) and from
use of cyanide as a suicide, homicide, or chemical warfare agent
[13–15] (e.g., in World War  I, II, Tokyo subway attack, etc. [1]). The
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availability of cyanide, due to its versatile use in industrial pro-
cesses (e.g., electroplating and plastic processing) and its rapidly
acting nature, makes it an important threat to mankind [1,16].
Currently, there are three major classes of cyanide therapeutics
that are approved by the U.S. Food and Drug Administration (FDA):
methemoglobin generators, direct sequestering agents, and sulfur
donors [3,17–19].
Sodium nitrite, primarily classified as a methemoglobin gener-
ator, is generally agreed to function by indirect sequestration of
cyanide [20]. Nitrite oxidizes ferrous (2+) iron to ferric (3+) iron in
hemoglobin to form methemoglobin, which strongly binds cyanide
to form cyanomethemoglobin. Methemoglobin serves as a tempo-
rary binding site for cyanide ion, and thus transiently decreases free
cyanide in the bloodstream. Another recently proposed alternative
mechanism of action is the conversion of nitrite to nitric oxide,
which can then displace cyanide bound to cytochrome c oxidase
[21,22]. After displacement, cyanide is subsequently converted to
less harmful compounds through normal metabolism or neutral-
ized via a combination therapy (e.g., thiosulfate) [22]. With either
http://dx.doi.org/10.1016/j.chroma.2016.07.046
0021-9673/© 2016 Elsevier B.V. All rights reserved.
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Fig. 1. Schematic representation of the reaction of DMTS and cyanide to form
dimethyl disulfide (DMDS) and thiocyanate.
detoxification mechanism, the major limitation of sodium nitrite
is the production of methemoglobin. Excessive methemoglobin
production (>30%) is a health risk, especially in children, leading
to headaches, cyanosis, fatigue, coma, and even death [17]. Addi-
tionally, conversion of hemoglobin to methemoglobin lowers the
oxygen carrying capacity of the blood, which can exacerbate car-
bon monoxide-induced reduction in oxygen carrying capacity in
smoke-inhalation victims [3,20].
While sodium nitrite indirectly binds cyanide, hydroxocobal-
amin acts by directly sequestering cyanide [3,23,24]. The high
affinity of cyanide towards the cobalt atom in hydroxocobalamin
allows the formation of cyanocobalamin, which is easily excreted
from the body in the urine. Although administration of hydroxo-
cobalamin produces only mild side effects, it requires a high dose
for optimum therapeutic effect (5 g administered over 15 min) [24].
Therefore, hydroxocobalamin typically needs to be administered
intravenously by trained personnel over a long period of time,
which severely limits its applicability during mass casualty events
[3,17].
Sodium thiosulfate is the only currently approved sulfur donor,
the third class of cyanide antidote, for treatment of cyanide poison-
ing. It donates a sulfur to cyanide, converting it to minimally toxic
and renally excreted thiocyanate [25,26]. Although sodium thiosul-
fate has few adverse effects, its antidotal activity is mainly limited
by its short biological half-life, small volume of distribution, and
its dependence on rhodanese to aid sulfur transfer [3]. Rhodanese
is a sulfur transferase enzyme primarily located in mitochondria
of the liver and kidneys, with low concentrations in the brain, an
organ most susceptible to cyanide-induced histotoxic anoxia. The
limited lipophilicity of thiosulfate as a result of its anionic charge,
also adversely impacts its ability to penetrate the cell and reach the
mitochondrial rhodanese [3].
Considering the serious limitations of the current antidotes,
several investigations have been in progress to develop the next
generation of cyanide therapeutics [19,25–29]. One promising
approach is the development of a sulfur-donating compound that
works effectively with or without rhodanese [25,26]. Based on
this approach, numerous synthetic and naturally occurring sulfur
donors have been evaluated for in-vitro and in-vivo efficacy [3],
with dimethyl trisulfide (DMTS) suggested as the most promising
next generation sulfur donor for treatment of cyanide poisoning.
The reaction by which DMTS detoxifies cyanide into thiocyanate
is shown in Fig. 1. The rhodanese sulfur transfer mechanism is
well-discussed in the literature [30]. However, the mechanism of
direct DMTS sulfur transfer is not well understood, but is known
to occur [31]. Moreover, the high lipophilicity of DMTS permits its
effective penetration of the cell membrane and the blood brain bar-
rier, allowing better in-vivo antidotal efficacy than thiosulfate [31].
Recent in vitro studies demonstrate that, compared to sodium thio-
sulfate, DMTS is 43 times more effective at detoxifying cyanide in
the presence of rhodanese [31]. Whereas, in absence of rhodanese,
the difference in efficacy is even higher, with DMTS producing 79
times greater efficacy than thiosulfate [31]. These results are con-
sistent with in vivo studies, where the therapeutic antidotal ratio
of DMTS was more than triple of what was observed for thiosul-
fate at the same dose. The in vivo and in vitro efficacy data confirm
that DMTS is a superior cyanide countermeasure compared to the
present sulfur donor therapy of thiosulfate.
Despite the potential advantages of DMTS, the lack of a validated
analytical method for its analysis may  limit vital studies for ther-
apeutic translation of DMTS. The only relevant report in regards
to analysis from a biological matrix was  published by Shirasu and
coworkers, where DMTS was  identified as a source of sulfurous
malodor in fungating cancer wounds [32]. However, the concen-
trations of DMTS were not well quantified, and the method was
not validated. Besides this single study, DMTS has mainly been
identified as a naturally occurring compound contributing to pun-
gent odors in vegetables such as garlic, soy, cabbage, broccoli, and
cauliflower [32–36]. In addition, it has also been detected or quan-
tified from fermented and aged food (cheese) and drinks (milk,
beer [37], sake, and wine), where it most likely comes from oxida-
tion of methanethiol, a bacterial degradation product of methionine
[32,38–42]. The analysis of DMTS is typically accomplished using
headspace analysis or solid-phase microextraction with GC–MS.
While these analytical techniques provide direction for the analysis
of DMTS from blood, a validated analytical method is not currently
available (from any matrix), but is critical for further development
of this promising antidote. Therefore, the objective of the current
study was  to develop a validated method for the analysis of DMTS
from whole blood. To accomplish this objective, a stir bar sorptive
extraction (SBSE) GC–MS analysis technique for analysis of DMTS
from rabbit whole blood samples was developed.
2. Experimental
2.1. Reagents and standards
All reagents were at least reagent grade unless otherwise noted.
Methanol (LC–MS grade) and nitric acid were purchased from
Fisher Scientific (Fair Lawn, NJ, USA). Reverse-osmosis water was
purified to 18.2 M-cm using a polishing unit from Lab Pro, Lab-
conco (Kansas City, KS, USA). Dimethyl trisulfide (DMTS) was
obtained from Sigma-Aldrich (St. Louis, MO,  USA). Gerstel Twister®
stirbars (film thickness 0.5 mm,  length 10 mm)  were purchased
from Gerstel, Inc. (Linthicum, MD,  USA). Isotopically labeled inter-
nal standard (IS), dimethyl-d6-trisulfide (DMTS-d6), was  acquired
from US Biological Life Sciences (Salem, MA,  USA). DMTS stock solu-
tion was prepared fresh for each experiment. The internal standard
solution was  prepared from a 10 mM stock solution in methanol
stored at −30 ◦C.
2.2. Biological fluids
For method development and validation, rabbit whole blood
(EDTA anti-coagulated) was  purchased from Pelfreeze Biological
(Rogers, AR, USA) and stored at −80 ◦C until used. Rabbit whole
blood was  used to develop the method presented here because we
planned to utilize a rabbit model developed by our collaborators
to prove the applicability of the analytical method for the analy-
sis of blood DMTS concentrations. However, at the time we  were
finalizing the method validation, efficacy studies of DMTS were
transitioned to a mouse model. Male Charles River (North Carolina,
USA) CD-1 mouse (18–20 grams) blood from DMTS efficacy studies
was gathered at Sam Houston State University. DMTS was intra-
muscularly administered at 200 mg/kg. The mice were anesthetized
(after 10 min) and placed on isoflurane. Blood was collected intra-
venously using a heparinized Pasteur pipette and transferred to
heparinized 1.5 mL  centrifuge tubes. An aliquot of blood (∼150 L)
was then frozen and shipped on dry ice to South Dakota State Uni-
versity. Upon receipt, samples were stored at −80 ◦C until ready for
analysis. Due to the limited volume of mouse blood, each sample
(100 L) was transferred to a clean vial and diluted in DI water to
500 L before extraction and analysis.
All animals were handled in accordance with the Guide for
the Care and Use of Laboratory Animals [43] by an Association
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for the Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International accredited institution. The Institutional
Animal Care and Use Committee (IACUC) at Sam Houston State
University approved the experiment.
2.3. Sample preparation
Blood (450 L) was added to a 20 mL  glass scintillation vial. An
aliquot of aqueous nitric acid (1 mL,  90 mM)  was added to the blood
to lyse the red blood cells and denature the blood proteins. Where
appropriate, aqueous DMTS standard (25 L) was spiked into the
denatured blood to achieve the desired final DMTS concentration.
Whenever needed, internal standard (25 L) was spiked into the
prepared blood to produce a final concentration of 5 M DMTS-d6.
A PDMS-coated stir bar was then added to the mixture, the sample
was capped, and stir bar sorptive extraction was performed for 1 h
at 700 rpm. Following extraction, the stir bar was  removed from
the solution using a 2-inch Teflon-coated magnet. The stir bar was
gently dried by dabbing against a delicate task wipe and then trans-
ferred into a Thermal Desorption Unit (TDU) tube. The TDU tube was
then placed into an auto-sampler for follow-on thermal desorption
and GC–MS analysis. (Note: Because of the rapid enzymatic degrada-
tion of DMTS in blood, for all validation experiments, blood was acid
denatured before adding DMTS or IS in order to maintain the reported
concentration and minimize error occurring from the rapid decom-
position. The reported concentration of all DMTS standards, including
QCs and calibrators, excludes the acid dilution volume.)
2.4. GC–MS analysis of DMTS
After SBSE, stir bars were analyzed for DMTS and DMTS-d6
using an Agilent Technologies 7890A gas chromatograph with a
5975C inert XL electron ionization/chemical ionization mass selec-
tive detector with a Gerstel MPS  2XL series autosampler. To initiate
analysis of the stir bar, the TDU tube with stir bar was transferred
to the TDU injector and heated to transfer DMTS to the cooled
injection system (CIS). The initial TDU injector temperature was
maintained at 60 ◦C, and increased linearly to 250 ◦C at a rate of
720 ◦C/min. The final TDU injector temperature of 250 ◦C was main-
tained for 1 min. Desorbed analytes were transferred to the CIS
programmable temperature vaporization (PTV) type inlet in split-
less desorption mode with a TDU transfer temperature of 200 ◦C.
To transfer the analyte from the CIS to the GC column, the initial
CIS temperature (30 ◦C) was linearly increased to 200 ◦C at a rate of
12 ◦C/s before returning to its initial temperature. Lower CIS tem-
peratures, 10 and 0 ◦C, were evaluated. However, improvement of
the chromatography was not observed, likely due to the relatively
high boiling point of DMTS (170 ◦C).
A DB5-MS bonded-phase column (30 m × 0.25 mm I.D., 0.25 m
film thickness; J&W Scientific, Folsom, CA, USA) was used to sepa-
rate components of the sample with nitrogen as the carrier gas at a
flow rate of 1 mL/min and a column head pressure of 5.565 psi. The
GC oven temperature was initially held at 30 ◦C for 1 min, then ele-
vated at a rate of 120 ◦C/min to 250 ◦C, where it was  held constant
for 1 min, before returning to its initial temperature. The elapsed
time from adding the TDU tube to TDU until the end of the anal-
ysis was ∼ 9 min, which included transfer of the analyte from the
PDMS stir bar, through the TDU and CIS, and into the column. The
actual chromatographic acquisition time was 3.83 min with DMTS
and DMTS-d6 eluting at 2.9 min. The GC was interfaced with a mass
selective detector using electron ionization with an electron energy
of 70 eV. The MS  source and quadrupole temperatures were 250 ◦C
and 150 ◦C, respectively. Selective ion monitoring (SIM) was  used
to monitor the quantification and identification ions of DMTS (m/z
of 126 and 111, respectively) and DMTS-d6 (m/z of 132 and 114,
respectively).
2.5. Calibration, quantification, and limit of detection
Validation of this method was performed by generally following
Food and Drug Administration guidelines [44–46]. For calibra-
tion and quality-control (QC) standards, a combined DMTS and
IS aqueous solution was initially prepared to limit loss of DMTS
(i.e., loss from evaporation and degradation). Aqueous DMTS stan-
dard (100 L) was transferred via pipette to a 2 mL  glass vial, and
a cap with a septum was used to immediately seal the vial. To
the closed vial, IS (100 L of 200 M)  was  injected using a 1 mL
(0.33 × 12.7 mm)  syringe, and subsequently mixed to produce a
combined standard of DMTS and IS. This standard solution was
refrigerated at 4 ◦C until it was  used for the preparation of cali-
bration or QC standards. (Note: Mixing of DMTS and IS in a closed
vial using a syringe was a crucial step to prevent the rapid and uneven
evaporative loss of DMTS and IS when opening and closing vials. Addi-
tionally, it was important to introduce IS and DMTS to the blood
simultaneously to account for the rapid enzymatic degradation of
DMTS.) Calibration and QC standards were prepared by spiking the
combined standard (25 L) into 1475 L of denatured blood and
extracting as previously described in the sample preparation sec-
tion. Each calibration standard (0.5, 1, 2, 5, 10, 20, 50, and 100 M)
was prepared in triplicate. To obtain a calibration curve, the aver-
age peak-area signal ratios of DMTS to IS were plotted as a function
of concentration. Peak areas were calculated by manual integra-
tion from baseline to baseline in ChemStation software (Agilent
Technologies, Santa Clara, CA, USA). Five preliminary calibration
curves were constructed to evaluate the calibration behavior of
DMTS. Ultimately, a total of ten calibration curves constructed over
the course of preliminary studies and validation experiments con-
firmed that a non-linear power curve fit (y = axb) best described the
calibration behavior of DMTS.
The limit of detection (LOD) was  determined by analyzing mul-
tiple concentrations of DMTS in blood below the LLOQ. The LOD was
defined as the lowest DMTS concentration that reproducibly pro-
duced a signal-to-noise ratio of 3. Noise was  measured by averaging
the peak-to-peak noise in blank solutions over the retention time of
the analyte. The lower limit of quantification (LLOQ) and upper limit
of quantification (ULOQ) were defined as the lowest and highest
concentrations that satisfied the inclusion criteria of <15% relative
standard deviation (as a measure of precision), and a percent devia-
tion within ±15% back-calculated from the nominal concentration
(as a measure of accuracy) for all calibration standards within the
dynamic range. QC standards were prepared and analyzed in quin-
tuplicate at three concentrations not included in the calibration
curve: 1.5 M (low QC), 7.5 M (medium QC), and 35 M (high
QC). QCs were prepared fresh daily in order to calculate the intra-
assay (within same day) and inter-assay (over three separate days,
within six calendar days) accuracy and precision.
2.6. Selectivity and stability
The ability to differentiate and quantify DMTS in the presence
of other blood components (assay selectivity) was  determined by
comparing blank blood with DMTS spiked blood. The absence of
signals above the baseline in the blank over the elution time of
DMTS was  indicative of high selectivity.
Short- and long-term stability of DMTS was assessed by ana-
lyzing triplicates of low and high QCs in blood at different storage
conditions over multiple time periods. For short-term stability, pre-
pared QCs were evaluated in the autosampler, on the bench-top,
and under multiple freeze-thaw (FT) cycles. The autosampler sta-
bility was  evaluated by storing PDMS stir bars after SBSE extraction
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on the autosampler (at ambient temperature), and analyzing them
at approximately 0, 1, 5, 10, and 24 h. Internal standard was  not
used for the autosampler stability experiment, as it would correct
for the loss of DMTS during the storage time tested. The bench-top
stability was evaluated for two different conditions: non-denatured
blood and denatured blood. The low and high QCs for both condi-
tions were allowed to stand at room temperature for 0, 1, 2, 4, 8,
12, and 24 h prior to analysis.
For freeze-thaw stability of DMTS, four sets of QCs (low and high)
were prepared. One set of QCs was extracted and analyzed on the
same day while the other three sets were stored in a freezer at
−80 ◦C. After 24 h, all three sets of QCs were thawed by running
ambient tap water over the base of the sample vial. A single set of
thawed QCs was then extracted and analyzed, while the remaining
two sets were again stored at −80 ◦C for 24 h. The procedure was
repeated two more times to evaluate three freeze-thaw cycles.
Evaluation of long-term stability in blood was  conducted at
three storage conditions (−80, −20, and 4 ◦C). The low and high
QCs were analyzed in triplicate on the day they were prepared,
and after 1, 2, 5, 10, and 30 days. A simple experiment was  also
performed to test if loss of DMTS would be minimized by snap
freezing of blood samples before storage. Triplicates of high QCs
in blood were prepared and snap-frozen using a dry ice–acetone
bath before storing them at −80 ◦C. The recovery of these samples
was compared to non-snap frozen samples also stored at −80 ◦C.
For bench-top, freeze-thaw, and long-term stability experiments,
internal standard was spiked into the blood samples after comple-
tion of the storage period and prior to SBSE extraction to correct
for sample preparation and instrument variability. We  also eval-
uated the long-term stability of DMTS in PDMS-coated stir bars at
−80 ◦C. For this experiment, all stir bars were extracted at the same
time from a single denatured solution (50 mL  blood, 100 mL  90 mM
HNO3) of appropriate QC concentration (low and high). For each
QC solution, fifteen PDMS stir bars (triplicates for 5 storage days)
were anchored on a 3-inch cylindrical magnetic stir bar, which was
used to stir the denatured blood solution for 1.5 h to perform SBSE.
After extraction, the PDMS stir bars were transferred into 2 mL  glass
vials and capped. The stir bars were analyzed on the day they were
prepared, and after 1, 5, 10, and 40 days. Since IS could not be used
for this experiment, triplicate of a 5 M aqueous DMTS solution
was prepared, extracted using SBSE, and analyzed on each day the
QCs were evaluated for stability in order to correct for instrument
variability over different days. For all stability experiments, signal
stability was calculated as a percentage of the initial “time-zero”
signal. DMTS was considered stable if the stored sample signal
stability percentage was within 10% of time zero.
Finally, to verify if the IS corrects for the loss of DMTS during
storage and sample preparation, a 5-day stability test was  per-
formed. The QCs (low and high) were prepared by spiking the
combined standard of DMTS and IS, and were stored at −80 ◦C for 1,
2, and 5 days. When ready to analyze, the QCs were thawed, dena-
tured with acid, and extracted using SBSE. The DMTS/IS ratio for
each day was calculated and compared to Day 0.
2.7. Recovery and matrix effect
Recovery of DMTS was evaluated by analyzing triplicates of low,
medium, and high aqueous QCs, and comparing them with the
equivalent QCs in blood. Recovery was calculated as a percentage by
dividing the analyte signal in blood by the aqueous signal. Recov-
ery calculated in this manner will be influenced by blood matrix
effects, and therefore, may  not reflect a true estimate of recovery. A
true recovery from blood cannot be measured discretely, but may
be estimated once matrix effects are assessed. Matrix effects were
assessed by comparing the aqueous calibration curve with the cal-
ibration curve of DMTS in blood. The deviation of b in the power-fit
Fig. 2. Total ion GC–MS chromatograms of non-spiked blood (lower trace, listed as
“Blank”) and selected ion chromatograms of 1 M DMTS (middle traces) and 1 M
DMTS-d6 (upper traces). DMTS quantification and identification ions (m/z 126 and
111, respectively) and DMTS-d6 quantification and identification ions (m/z 132 and
114, respectively) are separately plotted.
equation (y = axb) gave a measure of the magnitude of the matrix
effects.
3. Results and discussion
3.1. GC–MS analysis of DMTS from rabbit blood
The method presented here includes an easy one-pot sample
preparation scheme for extraction of DMTS from whole blood. The
whole blood is simply treated with acid to lyse RBCs and denature
proteins, and then a PDMS stir bar is directly added to the resulting
solution. After an hour of SBSE, the stir bar is then analyzed via
GC–MS by thermally desorbing the DMTS in the TDU.
SBSE was  chosen for sample preparation of DMTS because it has
a relatively high phase ratio, SBSE is a single-step solventless pro-
cess, and it is typically highly reproducible [47]. Specifically, the
analysis of DMTS using SBSE takes advantage of the relatively high
octanol-water distribution co-efficient of DMTS (log Kow = 1.87).
Assuming equilibrium is reached and the Kow of DMTS is a good
estimate of the KPDMS, approximately 54% of the DMTS should
reside in the PDMS layer of the stir bar (film thickness 0.5 mm,
length 10 mm),  when the sample volume is 1.5 mL  (i.e., the final
sample volume used in the current method). The overall sam-
ple preparation time is 1 h 10 min, with thermal desorption and
chromatographic analysis lasting approximately 15 min  (including
equilibration time for the following sample). Using this method,
roughly 90 individual samples could be processed and analyzed in
a 24 h time period.
The total ion chromatogram (TIC) of blank blood and selected
ion chromatograms (m/z = 111, 114, 126 and 132) of spiked (1 M
DMTS and 1 M IS) blood are plotted in Fig. 1. The peaks for DMTS
and IS eluted at approximately 2.9 min. The method showed excel-
lent selectivity with no interfering or co-eluting peaks in the blank.
Quantification ions of DMTS (m/z of 126) and IS (m/z of 132), and
identification ions of DMTS (m/z of 111) and IS (m/z of 114) are
plotted in Fig. 2.
3.2. Dynamic range, limit of detection, and sensitivity
Calibration curves for DMTS were constructed in the range of
0.2–200 M in blood. Upon analysis of multiple calibration curves
using linear (non-weighted and weighted), power, and quadratic
fits, we  determined that the calibration behavior of DMTS followed
a power curve (y = axb). Using a power fit, 0.2 and 200 M calibra-
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Table  1
Curve equations and R2 values for separate calibration curves prepared over a three-
day  period.
Days Equation R2
Day 1 y = 0.1184 x1.18 0.9984
Day  2 y = 0.1321 x1.21 0.9992
Day  3 y = 0.1232 x1.19 0.9984
tors did not meet the accuracy and/or precision inclusion criteria,
and were excluded. Therefore, the dynamic range for the method
was from 0.5 M (LLOQ) to 100 M (ULOQ), with a correlation co-
efficient (R2) > 0.998 (Table 1). Table 1 shows that the b-term of the
calibration equation (y = axb) remained consistent over the three
calibration curves, producing a relative standard deviation of ≤2%,
confirming the uniform calibration behavior of DMTS.
The dynamic range of the method spanned over two orders of
magnitude, which is typically good for analysis from biological sam-
ples [48,49], and should be useful for therapeutic studies where a
large range of concentrations is administered. The method achieved
an excellent LOD, 60 nM in blood, as compared to other similar
methods for therapeutics [19,49,50]. The low limit of detection is
most likely attributed to the efficient pre-concentration of DMTS in
the PDMS layer of the stir bar.
The non-linear behavior of DMTS was verified by over than 10
calibration curves produced with the method presented here from
both blood and aqueous samples, and from direction injection of
DMTS calibration standards. Non-linear calibration behavior when
directly injecting DMTS calibration standards, suggests that the
non-linearity did not stem from the extraction process or from
the matrix components. This behavior is most likely caused by
either higher concentrations of DMTS enhancing the MS  ioniza-
tion process (i.e., more DMTS molecular ions are produced as the
concentration of DMTS in the ionization chamber increases) or
adsorptive losses at low DMTS concentrations (i.e., a small amount
of high affinity sites binding DMTS, with greater amounts of DMTS
overwhelming these high affinity sites). Evaluation of the peak
shape and calibration behavior of the low and high concentration
calibrators indicated no evidence of adsorptive losses. Therefore, it
is most likely that the ionization of the DMTS molecular ion, the ion
used for quantification, is enhanced at higher concentrations. This
may  occur if DMTS molecular ions assist in ionization of more DMTS
molecules through energy transfer, similar to chemical ionization.
3.3. Accuracy and precision
The accuracy and precision of the method, as determined by
quintuplicate analysis of low (1.5 M),  medium (7.5 M),  and high
(35 M)  QCs, on three different days (within a 6-day period), are
reported in Table 2. Considering that DMTS is vulnerable to rapid
enzymatic degradation and evaporative loss, the accuracy and pre-
cision of the method were remarkable. The intra-assay accuracy
(100 ± 7–14%) and precision (<2–10% RSD), and inter-assay accu-
racy (100±11%) and precision (<6% RSD) of this method were
excellent and well within the FDA method validation guidelines
[44–46,48].
3.4. Matrix effects and recovery
The assessment of matrix effects provides a measure of ion sup-
pression or enhancement leading to loss or gain of analyte signal.
It is typically calculated by comparing the slope of the calibration
curve in blood with that of the aqueous calibration curve. For a non-
linear power trend, the power (b) in y = axb translates to the slope
in a linear fit. Hence, matrix effects were evaluated by calculat-
ing the ratio of power coefficient of the calibration curve in blood
to that in aqueous. This ratio, determined as 0.96, indicated that
matrix effects were essentially negligible for the analysis of DMTS
in blood. The minimal matrix effect can be attributed to the fact
that only hydrophobic analytes are efficiently extracted into the
PDMS-coated stir bar. This minimizes the interference from other
blood components during DMTS analysis. Note that the power coef-
ficients of IS-corrected aqueous and blood calibration curves, were
even closer to each other (Powerblood/Poweraq = 0.998), which gives
another indication of effectiveness of the IS in correcting for any loss
of DMTS signal during the analysis process.
Assay recovery of DMTS for low, medium, and high QCs was
66, 63, and 59% respectively. Incomplete recovery can be partly
attributed to the rapid enzymatic degradation of DMTS in blood.
Although the acid concentration and volume were optimized for
the best recovery, the acid-denaturation process may  not suffice
in completely halting all enzymatic activity. Additionally, lower
recovery can also be explained by the hydrophobic nature of DMTS.
Since some components of blood provide a more hydrophobic
environment than water, these components may interfere with
effective partitioning of DMTS into the PDMS layer of the stir bar.
Nevertheless, the recovery for all low, medium, and high QCs was
very consistent, and sufficient to achieve detection at concentra-
tions as low as 60 nM.  It is unlikely that lower recovery is caused
from evaporative loss, since both the aqueous and blood samples
undergo same sample preparation steps. Therefore, loss of DMTS
from evaporation should be comparable.
3.5. DMTS storage stability
The bench-top stability of DMTS was  evaluated for low and high
QCs in both non-denatured and denatured blood for 0, 1, 2, 4, 8,
12 and 24 h. At 1 h, DMTS was undetectable in the non-denatured
blood, whereas 65% of the signal was recovered from the denatured
blood. This observation confirms that enzyme metabolism and/or
protein binding comprise a key loss mechanism for DMTS. Although
DMTS was detectable in the denatured blood, it is still considered
unstable (<90% of the original signal was recovered) at 1 h.
Auto-sampler stability, following stir bar extraction of DMTS,
was tested for 0, 1, 5, 10, and 24 h, during which, DMTS was stable
for the 24 h time period tested (i.e., the DMTS signals at different
time periods randomly deviated above and below the time zero
Table 2
The accuracy and precision for the analysis of DMTS in spiked blood by SBSE-GCMS.
Concentration (M) Intra-assay Inter-assay
Accuracy (%)a Precision (%RSD)a Accuracy (%)b Precision (%RSD)b
Day1 Day2 Day3 Day1 Day2 Day3
1.5 100 ± 12.5 100 ± 6.7 100 ± 13.5 9.4 6.3 2.1 100 ± 10.8 5.9
7.5  100 ± 0.1 100 ± 0.2 100 ± 8.3 0.9 0.6 1.1 100 ± 2.8 4.9
35  100 ± 6.5 100 ± 7.6 100 ± 6.5 0.7 1.2 1.3 100 ± 6.9 0.6
a QC method validation (N = 5).
b Mean of three different days of QC method validation (N = 15).
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Fig. 3. Evaluation of the ability of the IS to correct for signal loss during storage at −80 ◦C. (A) DMTS signal stability plotted without IS correction. (B) IS corrected DMTS
signal  stability. The uncorrected DMTS signal clearly decreases from Day 0 (due to loss during storage and freeze-thaw process) and has high variability (due to variation
in  instrument sensitivity and stir bars). The IS corrected stability remains consistent throughout the time tested, with the IS correcting the DMTS signal for significant loss
mechanisms.
signal; the variability was likely caused by differences between stir
bars and slight changes in instrument sensitivity over time).
Long-term stability was evaluated for low and high QCs by stor-
ing them at −80, −20, and 4 ◦C over a 30-day period. DMTS was
rapidly removed from blood when stored at −20 and 4 ◦C, with
less than 10% signal recovered after one day relative to the initial
time. However, at −80 ◦C, although some of the DMTS signal was
lost (20–50%), the concentration stayed consistent over the 30 day
period with no trend of further loss. The rapid loss at higher temper-
atures (−20 and 4 ◦C) likely results from the enzymatic activity of
blood proteins. At −80 ◦C, the rapid initial loss may  have resulted
from DMTS degradation during the delay times between spiking
DMTS and complete freezing, and/or during thawing prior to acid
addition. In order to reduce the initial delay time of complete freez-
ing, blood samples were snap frozen using dry ice and acetone bath
before transferring to a −80 ◦C freezer. Results from this experi-
ment showed similar recovery for the snap frozen (79 ± 9.6%) and
non-snap frozen (72 ± 12.8%) samples. This suggested that the sig-
nificant loss mainly takes place during the thawing process, and
that snap freezing prior to storage does not provide a definite
advantage.
Long-term stability of DMTS in the stir bar was evaluated at
−80 ◦C for 0, 1, 5, 10, and 40 days to determine if the samples could
be prepared and the stir bars analyzed at a later date. The signal
ratio of DMTS to positive control was determined to compare the
stability of DMTS over different days. The high QCs were stable in
the stir bar for 5 days (i.e. signal within 100 ± 10%), whereas, the low
QCs were considered unstable on Day 5. On Day 40, both QCs (high
and low) were considered unstable with signal loss of 30–40%.
The freeze-thaw stability test showed that DMTS is lost with
each freeze-thaw cycle, which was in agreement with our findings
from long-term stability of DMTS in blood at −80 ◦C. During the
freeze-thaw cycle, DMTS is rapidly lost from the blood likely due
to the enzymatic activity. Hence, freezing and thawing should be
avoided, but if freezing the blood is necessary, then acid should be
added immediately after thawing in order to help preserve DMTS.
The 5-day stability study using QCs (low and high) showed that
when IS was spiked before storage, the DMTS to IS ratio remained
consistent throughout the storage time, verifying that the IS effec-
tively corrected for any loss of DMTS during storage. Fig. 3 shows
the ability of the IS to correct for signal loss during storage. Fig. 3A
illustrates DMTS stability without IS correction, where DMTS sig-
nal is seen to significantly deviate compared to the Day 0 signal.
Fig. 3B shows the DMTS to IS signal ratio for all days. When com-
paring these two  graphs, it is obvious that the IS corrects for the
large signal loss due to instability of the DMTS.
Overall, our results from the stability studies suggest that blood
samples should be denatured with acid, spiked with IS, extracted
and analyzed immediately whenever possible. In any circumstance
where immediate analysis is not possible, the blood samples should
be spiked with IS, frozen as soon as possible, and stored at −80 ◦C for
future analysis. Once the frozen samples are thawed, they should
be prepared and extracted immediately. Once extracted into the
PDMS layer, DMTS is stable for at least 24 h on the auto-sampler at
ambient temperature. While the DMTS is stable in the stir bar at
−80 ◦C for 24 h, it is not recommended to store the stir bar under
these conditions unless it is absolutely necessary.
3.6. Analysis of DMTS exposed animals
The validated SBSE GC–MS method was applied to the analysis
of DMTS from blood samples of treated mice. The GC–MS chro-
matograms of treated and untreated mouse blood are shown in
Fig. 4. DMTS was detected as a prominent peak at 2.9 min from
DMTS- treated mouse blood, whereas no peak was  present in the
untreated blood. This further verified the selectivity of the method
and confirmed its applicability to authentic samples from treated
animals.
4. Conclusion
A simple and sensitive analytical method for the determination
of DMTS in blood was  developed using SBSE-GCMS. The method
presented is the first validated method for DMTS analysis from any
matrix. The described method is simple, with easy one-pot sample
preparation and extraction. The method yielded excellent accu-
racy and precision, consistent recovery, minimal matrix effects, an
excellent detection limit, and a large dynamic range that spanned
over 2 orders of magnitude. The ability to store internal standard
spiked samples was  also demonstrated. The creation of this method
is significant, since there are no analytical methods currently avail-
able for analysis of DMTS from blood and the first validated method
in any matrix. The availability of this method will allow further
drug development investigations of DMTS as a promising cyanide
antidote.
16 E. Manandhar et al. / J. Chromatogr. A 1461 (2016) 10–17
Fig. 4. GC–MS chromatograms (SIM, m/z 126) for DMTS treated (200 mg/kg, intramuscular administration) and untreated mice blood, and DMTS spiked and non-spiked
rabbit  blood.
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